| Coefficient (B) | 95%CI | Standard coefficient (β) | P-Value | Adjusted R2 |
---|---|---|---|---|---|
Primary outcome: ZBI | |||||
 Groupa | −1.427 | (−7.452 ~ 4.597) | −.044 | 0.636 | 0.587 |
 Baseline outcome score | .701 | (0.498 ~ 0.904) | .710 | < 0.001*** | |
 Baseline NPI-Q distress score | .257 | (−0.145 ~ 0.659) | .130 | 0.205 | |
Secondary outcomes: PHQ-9 | |||||
 Groupa | −2.302 | (−4.543 ~ −0.061) | −.202 | 0.044* | 0.527 |
 Baseline outcome score | .417 | (0.194 ~ 0.640) | .393 | < 0.001*** | |
 Baseline NPI-Q distress score | .318 | (0.175 ~ 0.462) | .464 | < 0.001*** | |
Secondary outcomes: The Fear of COVID-19 Scale | |||||
 Groupa | 2.782 | (0.982 ~ 4.573) | .261 | 0.003** | 0.654 |
 Baseline outcome score | 0.715 | (0.555 ~ 0.880) | .745 | < 0.001*** | |
 Baseline NPI-Q distress score | 0.034 | (−0.102 ~ 0.114) | .037 | 0.656 | |
Secondary outcomes: α-amylase activity in salivab | |||||
 Groupa | −.704 | (−1.409 ~ 0.000) | −.265 | 0.050 | 0.192 |
 Baseline outcome score | .447 | (0.148 ~ 0.746) | .405 | 0.004** | |
 Baseline NPI-Q distress score | .016 | (−0.026 ~ 0.059) | .103 | 0.445 |